Clinical Trial Update: Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI [Phase 2]

View source ↗

Summary

Phase 2 trial assessing imatinib dose escalation to 800 mg/day in Korean patients with metastatic or unresectable GIST harboring KIT exon 9 mutation (KENEDI).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: Asan Medical Center | Conditions: Gastrointestinal Stromal Tumors | Phase 2 | Status: UNKNOWN